PGIM Active Aggregate Bond ETF (PAB)

NYSEARCA: PAB · Real-Time Price · USD
41.88
-0.04 (-0.10%)
At close: Jun 8, 2026, 4:00 PM EDT
41.88
0.00 (0.00%)
After-hours: Jun 8, 2026, 8:00 PM EDT
Assets$70.17M
Expense Ratio0.19%
PE Ration/a
Shares Out1.68M
Dividend (ttm)$1.92
Dividend Yield4.58%
Ex-Dividend DateMay 29, 2026
Payout FrequencyMonthly
Payout Ration/a
Volume10,321
Open41.98
Previous Close41.92
Day's Range41.87 - 41.98
52-Week Low41.23
52-Week High43.55
Beta0.25
Holdings421
Inception DateApr 12, 2021

About PAB

Fund Home Page

The PGIM Active Aggregate Bond ETF (PAB) is an exchange-traded fund that mostly invests in investment grade fixed income. The fund is an actively managed fixed income fund that holds USD-denominated securities issued by both government and corporate entities. These securities must be investment grade and have maturities of more than one year. PAB was launched on Apr 12, 2021 and is issued by PGIM.

Asset Class Fixed Income
Category Intermediate Core Bond
Stock Exchange NYSEARCA
Ticker Symbol PAB
ETF Provider PGIM

Dividend History

Ex-DividendAmountPay Date
May 29, 2026$0.2042Jun 2, 2026
Apr 30, 2026$0.1471May 4, 2026
Mar 31, 2026$0.1541Apr 2, 2026
Mar 2, 2026$0.1469Mar 4, 2026
Feb 2, 2026$0.1519Feb 4, 2026
Dec 30, 2025$0.2056Jan 2, 2026
Full Dividend History

Performance

PAB had a total return of 5.26% in the past year, including dividends. Since the fund's inception, the average annual return has been 0.13%.

News

PGIM Announces Net Asset Value Restatement for Three Exchange-Traded Funds (PAB, PSDM, PTRB)

NEWARK, N.J.--(BUSINESS WIRE)--This restatement is the result of an accounting error in calculating each exchange-traded fund's NAV by a third-party administrator.

Other symbols: PRUPTRB
5 days ago - Business Wire

Patrys Limited Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight

MELBOURNE--(BUSINESS WIRE)---- $PAB #antibody--Patrys Limited (ASX:PAB), a therapeutic antibody development company, has announced the publication of preclinical data for its therapeutic antibody cand...

5 years ago - Business Wire